Nanoptima
1 known investors
Find your way into Nanoptima
473 people in our graph share verified history with the Nanoptima team — schools, employers, funds. One of them is your warm intro.
Dominic Jacquessonunlockedknows Ned Wakeman · together at University of Oxford (overlapped)
×4knows the team · via University of Oxford
×6knows the team · via Colgate University
knows the team · via Yale School of Medicine
Nanoptima develops drug delivery technologies for ophthalmic applications, focusing on biomaterial-based solutions for retinal and eye diseases. The company draws on deep pharma and biotech expertise to advance formulation science and delivery mechanisms for pharmaceutical treatments.
Founders & leadership
NW
Ned WakemaninCEONed Wakeman founded and leads Nanoptima, which develops biomaterial-based drug delivery technologies for retinal and eye diseases. He has prior experience in life science business development, venture capital, and investment banking, and has directed oncology development programs funded by Cancer Research UK and InnovateUK.
Board
SF
Stephen FromChairman
Investors · 1
Companies House · registry record
View on Companies House ↗- Registered name
- NANOPTIMA LIMITED
- Company number
- 09998528
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 10 Feb 2016
- Registered office
- Suite 21g3, Alderley Park Congleton Road, Nether Alderley, SK10 4TG
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 28 Feb 2025 · next due 30 Nov 2026
- Confirmation statement
- last made up to 4 Jan 2026 · next due 18 Jan 2027
Current officers · 3
- Kevin Pritchard — director, appointed 24 Mar 2022
- Edward Wakeman — director, appointed 10 Feb 2016
- Deepbridge Ned Limited — corporate director, appointed 5 Jun 2026
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Nanoptima do?
- Nanoptima develops drug delivery technologies for ophthalmic applications, focusing on biomaterial-based solutions for retinal and eye diseases. The company draws on deep pharma and biotech expertise to advance formulation science and delivery mechanisms for pharmaceutical treatments.
- Who are Nanoptima's investors?
- Nanoptima's investors include Deepbridge Capital.